Evaluation of platelet function in essential thrombocythemia under different analytical conditions

References

• Rumi E, Cazzola M. How i treat essential thrombocythemia. Blood 2016;128:2403–2414. doi:10.1182/blood-2016-05-643346
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, Andersson TML. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: A population-based cohort study. Ann Intern Med 2018;168:317–325. doi:10.7326/M17-0028
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from european leukemianet. Leukemia 2018;32:1057–1069. doi:10.1038/s41375-018-0077-1
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 2018;8:2. doi:10.1038/s41408-017-0041-8
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589–604. doi:10.1055/s-2006-949664
   PubMed Web of Science ®Google Scholar
• Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule adp in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 1984;103:894–904.
   PubMed Web of Science ®Google Scholar
• Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemost 1979;42:794–796.
   PubMed Web of Science ®Google Scholar
• Swart SS, Pearson D, Wood JK, Barnett DB. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. Thromb Res 1984;33:531–541.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523–530. doi:10.1016/j.exphem.2005.01.015
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the jak2 mutational status. Haematologica 2006;91:169–175.
   PubMed Web of Science ®Google Scholar
• Maugeri N, Malato S, Femia EA, Pugliano M, Campana L, Lunghi F, Rovere-Querini P, Lussana F, Podda G, Cattaneo M, et al. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood 2011;118:3359–3366. doi:10.1182/blood-2011-02-337337
   PubMed Web of Science ®Google Scholar
• Spivak JL. Myeloproliferative neoplasms. N Engl J Med 2017;376:2168–2181. doi:10.1056/NEJMra1406186
   PubMed Web of Science ®Google Scholar
• Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 2005;409–415. doi:10.1182/asheducation-2005.1.409
   PubMedGoogle Scholar
• Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med 2001;5:79–87.
   PubMed Web of Science ®Google Scholar
• Briere JB. Essential thrombocythemia. Orphanet J Rare Dis 2007;2:3. doi:10.1186/1750-1172-2-3
   PubMed Web of Science ®Google Scholar
• Cesar JM, de Miguel D, Garcia Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, pfa-100. Am J Clin Pathol 2005;123:772–777.
   PubMed Web of Science ®Google Scholar
• Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, et al. The contribution of cyclooxygenase-1 and −2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010;115:1054–1061. doi:10.1182/blood-2009-08-236679
   PubMed Web of Science ®Google Scholar
• Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143–151.
   PubMed Web of Science ®Google Scholar
• Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225–1230.
   PubMed Web of Science ®Google Scholar
• van Genderen PJ, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: A rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999;104:438–441.
   PubMed Web of Science ®Google Scholar
• Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139–145.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost 1984;52:292–296.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: A consensus of the working party from the platelet physiology subcommittee of ssc/isth. J Thromb Haemost 2013. doi:10.1111/jth.12231
   Web of Science ®Google Scholar
• Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694–697.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–1372.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 world health organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14–22. doi:10.1038/sj.leu.2404955
   PubMed Web of Science ®Google Scholar
• Femia EA, Pugliano M, Podda G, Cattaneo M. Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets 2012;23:7–10. doi:10.3109/09537104.2011.596592
   PubMed Web of Science ®Google Scholar
• Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988;255:H1276–1288. doi:10.1152/ajpheart.1988.255.6.H1276
   PubMed Web of Science ®Google Scholar
• Dangelmaier CA, Holmsen H. Platelet dense granule and lysosome content. In: Harker LA, Zimmerman TS, editors. Methods in hematology: measurement of platelet function edinburgh. Scotaland: Churchill Livingstone; 1983. Vol. 92. p. 92–114.
   Google Scholar
• Drummond AH, Gordon JL. Rapid sensitive microassay for platelet 5ht. Thromb Diathes Haemorrh (Stuttg) 1974;31:366–367.
   PubMedGoogle Scholar
• Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european leukemianet. J Clin Oncol 2011;29:761–770. doi:10.1200/JCO.2010.31.8436
   PubMed Web of Science ®Google Scholar
• Finazzi G. How to manage essential thrombocythemia. Leukemia 2012;26:875–882. doi:10.1038/leu.2011.306
   PubMed Web of Science ®Google Scholar
• Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 1982;47:84–89.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Falanga A. Leukocytosis, jak2v617f mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb 2008;36:148–159. doi:10.1159/000175153
   PubMedGoogle Scholar
• Barbui T, Buelli M, Cortelazzo S, Viero P, De Gaetano G. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987;83:265–268.
   PubMed Web of Science ®Google Scholar
• Gibson BE, Buchanan MR, Barr RD, White JG. Primary thrombocythaemia in childhood: symptomatic episodes and their relationship to thromboxane a2, 6-keto-pge1 and 12-hydroxy-eicosatetraenoic acid production: A case report. Prostaglandins Leukot Med 1987;26:221–231.
   PubMedGoogle Scholar
• Laguna MS, Kornblihtt LI, Marta RF, Molinas FC. [thromboxane b2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide]. Medicina (B Aires) 2000;60:448–452.
   PubMed Web of Science ®Google Scholar
• Mayordomo O, Carcamo C, Vecino AM, Navarro JL, Cesar JM. Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia. Thromb Res 1995;78:315–321.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Gadisseur A, Lam KH, De Raeve H, Schroyens W. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in jak2-positive essential thrombocythemia and polycythemia vera. Acta Haematol 2015;133:56–63. doi:10.1159/000360388
   PubMed Web of Science ®Google Scholar
• Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979;54:1258–1271.
   PubMed Web of Science ®Google Scholar
• Parise P, Huybrechts E, Grasselli S, Falcinelli F, Nenci GG, Gresele P, Vermylen J. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders. Acta Haematol 1991;85:88–92. doi:10.1159/000204863
   PubMed Web of Science ®Google Scholar
• Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991;47:326–332.
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013;121:1701–1711. doi:10.1182/blood-2012-10-429134
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. Am J Hematol 2015;90:683–685. doi:10.1002/ajh.24037
   PubMed Web of Science ®Google Scholar
• Femia EA, Scavone M, Lecchi A, Cattaneo M. Effect of platelet count on platelet aggregation measured with impedance aggregometry (multiplate analyzer) and with light transmission aggregometry. J Thromb Haemost 2013;11:2193–2196. doi:10.1111/jth.12432
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008;87:269–276. doi:10.1007/s00277-007-0386-3
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T. V617f jak-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702–711.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Arellano-Rodrigo E, Alvarez-Larran A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009;94:1484–1488. doi:10.3324/haematol.2009.013375
   PubMed Web of Science ®Google Scholar
• Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30:S294–301.
   PubMed Web of Science ®Google Scholar